N-Acetyl Selank Amidate

Cognitive & neuro Research only Animal studies

Also called NA-Selank Amidate

Selank with the same end-capping treatment: acetylated at one end, amidated at the other, to resist enzymatic breakdown. The underlying seven-amino-acid sequence and its anti-anxiety activity are unchanged.

Evidence at a glance

Evidence
Animal studies — Not yet studied in people
Status
Research compound only
Dosing
No human study has set a dose

As with the capped Semax, nearly all the supporting evidence belongs to the parent peptide rather than this modified version.

What studies report

How it works

Same seven-residue core as Selank, acting on GABA and serotonin signalling and on BDNF. An acetyl cap at one end and an amide at the other slow the enzymes that would otherwise break it down.

Binds a receptor on the cell surface and signals inward

Where it acts

Brain

The library groups this compound under Cognitive & neuro. The diagram shows that target, not every tissue it reaches.

Illustrated

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Anxiety without sedationFocus under stressLonger-lasting alternative to plain Selank

Reasons people seek it out — not a list of proven effects.

In practice Unapproved use

Reported real-world use, not evidence and not a recommendation.

Status: Research compound. Not approved.

Route
Intranasal spray
Sequence
Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2
Available as
20 mg

Search PubMed for N-Acetyl Selank Amidate → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.